MNKD Stock Overview
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
MannKind Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.61|
|52 Week High||US$4.86|
|52 Week Low||US$2.49|
|1 Month Change||30.60%|
|3 Month Change||28.77%|
|1 Year Change||7.46%|
|3 Year Change||277.87%|
|5 Year Change||51.65%|
|Change since IPO||-93.45%|
Recent News & Updates
Mannkind Corporation: Ready For Your Biotech PortfolioSep 01
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)Aug 19
|MNKD||US Biotechs||US Market|
Return vs Industry: MNKD exceeded the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: MNKD exceeded the US Market which returned -14.9% over the past year.
|MNKD Average Weekly Movement||8.0%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: MNKD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MNKD's weekly volatility (8%) has been stable over the past year.
About the Company
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.
MannKind Corporation Fundamentals Summary
|MNKD fundamental statistics|
Is MNKD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MNKD income statement (TTM)|
|Cost of Revenue||US$52.81m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.37|
|Net Profit Margin||-127.93%|
How did MNKD perform over the long term?See historical performance and comparison